Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

@article{Overman2017NivolumabIP,
  title={Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.},
  author={Michael J Overman and Ray McDermott and Joseph L Leach and Sara Lonardi and Heinz-Josef Lenz and Michael Andew Morse and Jayesh Desai and Andrew Graham Hill and Michael Axelson and Rebecca Anne Moss and Monica V. Goldberg and Z Alexander Cao and J M Ledeine and Gregory A. Maglinte and Scott Kopetz and Thierry Andr{\'e}},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 9},
  pages={
          1182-1191
        }
}
BACKGROUND Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 37 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 96 extracted citations

Similar Papers

Loading similar papers…